Twist Bioscience Q2 2026 Earnings: Growth Holds Steady Amid Biotech Headwinds
Twist Bioscience Corporation (NASDAQ: TWST) delivered its fiscal second-quarter 2026 earnings report on Thursday, posting revenue of $82 million, up 18% from the same period last year. The company, known for its synthetic DNA and gene synthesis platforms, beat analyst estimates on the top line, but a wider-than-expected net loss of $0.42 per share left some investors underwhelmed.
CEO Emily Leproust highlighted that the growth was fueled by robust demand from biopharma and academic research customers, particularly in the areas of antibody discovery and CRISPR-based gene editing. “Our platform continues to gain traction as researchers seek faster, more reliable DNA synthesis,” Leproust said during the call. The company also noted that its data storage and next-generation sequencing (NGS) segments are showing early promise, though they remain small contributors to overall revenue.
However, the earnings call wasn’t all smooth sailing. CFO Jim Thorburn flagged that gross margins dipped slightly to 42.5%, pressured by higher raw material costs and investments in new manufacturing capacity. The company reaffirmed its full-year revenue guidance of $340–$350 million, which some analysts viewed as cautious given the current biotech funding environment. “Twist is executing well, but the macro backdrop—rising interest rates and tighter VC spending—means they can’t afford to be complacent,” noted Sarah Chen, an analyst at Leerink Partners.
Market reaction was muted, with shares slipping about 2% in after-hours trading. The broader biotech sector has been under pressure, with the XBI index down 12% year-to-date. Still, Twist’s management struck an optimistic tone, pointing to a pipeline of new product launches in the second half of the fiscal year, including an expanded synthetic biology kit for smaller labs.
“I’m tired of hearing about ‘potential’—show me the profits,” said Marcus Delgado, a retail investor from Austin, Texas, who has held Twist shares for two years. “They keep talking about data storage and CRISPR, but the bottom line is still bleeding red. At some point, promises don’t pay the bills.” In contrast, Dr. Linda Park, a biotech consultant in San Francisco, offered a more measured view: “Twist is playing the long game. The DNA synthesis market is still in its infancy, and they’re building the infrastructure. Q2 wasn’t a home run, but it’s a solid double.”
Looking ahead, analysts are watching for signs of margin improvement and whether Twist can capture a larger share of the fast-growing gene therapy market. Competitors like Ginkgo Bioworks and Codex DNA are also vying for the same customers, but Twist’s proprietary silicon-based platform gives it a cost advantage, at least on paper. For now, the company remains a bellwether for the synthetic biology sector—a space that promises big things but has yet to deliver consistent profitability.